Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tongren Wuji Baifeng Pill for hyperuricemia in chronic kidney disease
ChiCTR2200057385Phase 4Not yet recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of Tongren Wuji Baifeng Pill in hyperuricemia and chronic kidney disease (CKD) (2 arms), sponsored by Guang'anmen Hospital. Primary endpoint: Serum uric acid. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
Tongren Wuji Baifeng Pill
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2200057385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057385.